This assumption is supported by the loss of CYR61 and CTGF inhibition as well as the decrease in the YAP1 activation score observed at the very end of the in vivo tumor growth study 34 days post in vivo tumor cell implantation and 15 days post doxycycline treatment Fig. S3. This evidence concerns the gene CCN2 and neoplasm.